Routine Form 3 filing for a new officer — no trading signal. Monitor future Form 4 filings for any open-market purchases or sales by Zimmermann, which would provide insider sentiment.
Price Chart
Executive Summary
Tracy Zimmermann, Chief Scientific Officer of City Therapeutics, filed a Form 3 initial statement of beneficial ownership, reporting stock options to acquire 436,557 shares of common stock at exercise prices of $0.92 and $5.36. This is a routine insider filing required upon becoming an officer and contains no trading activity or material financial news.
Key Facts
- Tracy Zimmermann appointed Chief Scientific Officer of City Therapeutics, Inc.
- Form 3 filed on 2026-10-15, reporting initial beneficial ownership.
- Zimmermann holds four stock option grants totaling 436,557 shares of common stock.
- Options have exercise prices of $0.92 (three grants) and $5.36 (one grant).
- Options vest over time subject to continued service; no immediate open-market share ownership reported.
Financial Impact
No financial impact; filing is a routine initial ownership disclosure with no transaction or capital event.
Risk Factors
- No material risks identified from this filing; it is a standard initial beneficial ownership report.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001104659-26-116359 |
| Document: 0001104659-26-116359-index-headers.html | 0001104659-26-116359 |
| Document: 0001104659-26-116359-index.html | 0001104659-26-116359 |
| Document: 0001104659-26-116359.txt | 0001104659-26-116359 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13D | $20.79 | awaiting T+1 | — | $21.26 (+2.26%) |
Oct 26, 2026 today | SC 13G | $20.79 | awaiting T+1 | — | $21.26 (+2.26%) |
Oct 22, 2026 4d ago | SC 13G | $20.77 $20.77 | · 0.00% | ▲ +0.52% | $21.26 (+2.36%) |
Oct 19, 2026 7d ago | Insider Cluster | $20.83 $20.43 | ▼ −1.92% | ▼ −2.45% | $21.26 (+2.06%) |
Oct 19, 2026 7d ago | Press Release | $20.83 $20.43 | ▼ −1.92% | ▼ −2.45% | $21.26 (+2.06%) |
Oct 16, 2026 10d ago | 424B4 | $21.46 $20.83 | ▼ −2.94% | ▼ −3.27% | $21.26 (−0.93%) |
Oct 16, 2026 11d ago | EFFECT | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $21.26 (−5.09%) |
Oct 15, 2026 11d ago | 3 | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $21.26 (−5.09%) |
Oct 15, 2026 11d ago | 3 | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $21.26 (−5.09%) |
Oct 15, 2026 11d ago | 3 | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $21.26 (−5.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers